Titan Spine's interbody fusion implants reached a milestone — there have been 27,000 implantations of the Endoskeleton.
"The significant growth of Titan Spine observed in 2014 alone has been tremendous, and we are extremely well-positioned to continue our momentum in 2015 and beyond," said President Kevin Gemas. "Over the past year, Titan achieved several milestones that attributed to our global growth and further validated our position as the leader in surface technology."
Here are 10 things to know about this benchmark:
1. There was a 25 percent increase in the number of surgeries performed using the Endoskeleton in 2014 over 2013.
2. The Endoskeleton interbody fusion device achieved $26 million annualized sales revenue run rate.
3. In 2014, the company reported expanded Titan Spine device use in Europe.
4. Titan Spine achieved market registration approval in Australia and New Zealand for its products last year.
5. In 2014, the company also received FDA clearance for Endoskeleton TL, the first lateral device to feature Titan's surface technology. Titan launched this device late last year on a limited basis and plans to fully launch in the first quarter of 2015.
6. There is currently more than 7,000 Titan Spine implants used annually.
7. Titan Spine has more than 200 hospital customers, which is 40 percent greater than in 2013.
8. The company has more than 90 distributors in the United States.
9. Titan recently received FDA clearance for the next generation nanoLOCK surface technology, which is the first FDA-cleared interbody fusion device with nanotechnology. The company plans to commercialize this technology in the fourth quarter of this year.
10. There will be an additional interbody device planned for the first quarter of 2015.
"Not only did 2014 see significant sales growth, but the science of our surface technology is beginning to resonate deeply within the surgeon and scientific communities," said Vice President of Sales Steve Cichy.